Single agent daratumumab in advanced multiple myeloma possesses
significant efficacy even in an unselected

J 2019

Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population

MINARIK, Jiri, Ludek POUR, Vladimir MAISNAR, Ivan SPICKA, Alexandra JUNGOVA et. al.

Základní údaje

Originální název

Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population

Autoři

MINARIK, Jiri (203 Česká republika, garant), Ludek POUR (203 Česká republika), Vladimir MAISNAR (203 Česká republika), Ivan SPICKA (203 Česká republika), Alexandra JUNGOVA (203 Česká republika), Tomas JELINEK (203 Česká republika), Lucie BROŽOVÁ (203 Česká republika, domácí), Petra KRHOVSKA (203 Česká republika), Vlastimil SCUDLA (203 Česká republika) a Roman HAJEK (203 Česká republika)

Vydání

Biomedical Papers, Olomouc: Palacky University, Olomouc, Palacky University, 2019, 1213-8118

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.000

Kód RIV

RIV/00216224:14110/19:00108570

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.5507/bp.2018.064

UT WoS

000489991000015

Klíčová slova anglicky

multiple myeloma; relapsed and refractory; daratumumab; progression free survival; overall survival

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 1. 2020 13:23, Mgr. Tereza Miškechová

Anotace

V originále

Objective. The treatment of relapsed and refractory multiple myeloma (RRMM) remains challenging. The outcomes in highly pretreated populations are unsatisfactory and there is urgent need for novel and safe therapeutic approaches. Recently, daratumumab has been approved for RRMM with promising results even in monotherapy. The aim of this study was to assess the efficacy of single agent daratumumab outside a clinical trial. Patients and Methods. 14 patients with RRMM and significant pretreatment (median 4.5 previous lines) entered a specific healthcare program and received treatment with single agent daratumumab. They were followed for therapeutic response based on IMWG criteria, and incidence of adverse events. The data were collected using the Registry of Monoclonal Gammopathies. Results. The overall response rate was 38.5%. 23.1% of patients reached very good partial response, 15.4% reached partial remission, 15.4% had minimal response, 38.5% had stable disease and 7.7% had progressive disease. The median progression free survival was 4.6 months and median overall survival was not achieved. The toxicities were mostly mild, only infectious complications and hematological toxicity reached grade III. Conclusion. We conclude that daratumumab has significant activity in highly pretreated RRMM even as a single agent, with an acceptable toxicity profile and survival impact.

Návaznosti

NV17-29343A, projekt VaV

Název: Analýza mikroprostředí kostní dřeně u extramedulárního relapsu mnohočetného myelomu

Citovat

MINARIK, Jiri, Ludek POUR, Vladimir MAISNAR, Ivan SPICKA, Alexandra JUNGOVA, Tomas JELINEK, Lucie BROŽOVÁ, Petra KRHOVSKA, Vlastimil SCUDLA a Roman HAJEK. Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population. Biomedical Papers, Olomouc: Palacky University. Olomouc: Palacky University, 2019, roč. 163, č. 3, s. 279-283. ISSN 1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2018.064.

@article{1605016,
   author = {Minarik, Jiri and Pour, Ludek and Maisnar, Vladimir and Spicka, Ivan and Jungova, Alexandra and Jelinek, Tomas and Brožová, Lucie and Krhovska, Petra and Scudla, Vlastimil and Hajek, Roman},
   article_location = {Olomouc},
   article_number = {3},
   doi = {http://dx.doi.org/10.5507/bp.2018.064},
   keywords = {multiple myeloma; relapsed and refractory; daratumumab; progression free survival; overall survival},
   language = {eng},
   issn = {1213-8118},
   journal = {Biomedical Papers, Olomouc: Palacky University},
   title = {Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population},
   url = {http://dx.doi.org/10.5507/bp.2018.064},
   volume = {163},
   year = {2019}
}

TY  - JOUR
ID  - 1605016
AU  - Minarik, Jiri - Pour, Ludek - Maisnar, Vladimir - Spicka, Ivan - Jungova, Alexandra - Jelinek, Tomas - Brožová, Lucie - Krhovska, Petra - Scudla, Vlastimil - Hajek, Roman
PY  - 2019
TI  - Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population
JF  - Biomedical Papers, Olomouc: Palacky University
VL  - 163
IS  - 3
SP  - 279-283
EP  - 279-283
PB  - Palacky University
SN  - 12138118
KW  - multiple myeloma
KW  - relapsed and refractory
KW  - daratumumab
KW  - progression free survival
KW  - overall survival
UR  - http://dx.doi.org/10.5507/bp.2018.064
L2  - http://dx.doi.org/10.5507/bp.2018.064
N2  - Objective. The treatment of relapsed and refractory multiple myeloma (RRMM) remains challenging. The outcomes in highly pretreated populations are unsatisfactory and there is urgent need for novel and safe therapeutic approaches. Recently, daratumumab has been approved for RRMM with promising results even in monotherapy. The aim of this study was to assess the efficacy of single agent daratumumab outside a clinical trial. Patients and Methods. 14 patients with RRMM and significant pretreatment (median 4.5 previous lines) entered a specific healthcare program and received treatment with single agent daratumumab. They were followed for therapeutic response based on IMWG criteria, and incidence of adverse events. The data were collected using the Registry of Monoclonal Gammopathies. Results. The overall response rate was 38.5%. 23.1% of patients reached very good partial response, 15.4% reached partial remission, 15.4% had minimal response, 38.5% had stable disease and 7.7% had progressive disease. The median progression free survival was 4.6 months and median overall survival was not achieved. The toxicities were mostly mild, only infectious complications and hematological toxicity reached grade III. Conclusion. We conclude that daratumumab has significant activity in highly pretreated RRMM even as a single agent, with an acceptable toxicity profile and survival impact.
ER  -

MINARIK, Jiri, Ludek POUR, Vladimir MAISNAR, Ivan SPICKA, Alexandra JUNGOVA, Tomas JELINEK, Lucie BROŽOVÁ, Petra KRHOVSKA, Vlastimil SCUDLA a Roman HAJEK. Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected ''real-world'' population. \textit{Biomedical Papers, Olomouc: Palacky University}. Olomouc: Palacky University, 2019, roč.~163, č.~3, s.~279-283. ISSN~1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2018.064.

Podrobný výpis o publikaci